FDA advisors recommend against use of calcitonin salmon (a man-made version of the hormone found in salmon) for the treatment of postmenopausal osteoporosis because the potential cancer risks outweigh the benefits, Reuters reports.

Briefing materials prepared by the FDA say that the potential for cancer risk “appears plausible” and that “significant questions” remain about whether therapy is effective in reducing fractures.

Currently available as a nasal spray (Miacalcin, Fortical) or injectable solution (Miacalcin), calcitonin products accounted for about 5% of sales of osteoporosis medications in 2011, according to the report.

The FDA will make a final determination after considering the advisory committee’s recommendations.

Source:Reuters